Fosgonimeton & Athira Pharma: Clinical Trial Failures and Research Scandal

Fosgonimeton is the phosphate prodrug form of Dihexa developed by Athira Pharma for clinical use as an Alzheimer's disease treatment. While Dihexa is a research peptide sold as a research chemical, fosgonimeton represents the pharmaceutical industry's attempt to bring Dihexa into clinical practice through formal regulatory pathways. This effort has ended in complete clinical failure and significant research integrity concerns. Understanding fosgonimeton's journey—from promising basic research to failed clinical trials to corporate scandal—is essential for anyone considering raw Dihexa use.

What is Fosgonimeton?

Fosgonimeton (previously designated ATH-434) is the phosphate ester prodrug of Dihexa. In pharmaceutical terminology, a prodrug is an inactive or weakly active compound that is metabolised in the body to produce the active drug. Fosgonimeton is designed to be administered by intravenous infusion, where it is rapidly dephosphorylated to release active Dihexa.

The prodrug formulation was developed to address a key limitation of raw Dihexa: bioavailability. Dihexa is a hydrophilic peptide that does not readily cross the blood-brain barrier or achieve sufficient systemic circulation when administered directly. By adding a phosphate group, researchers hypothesised that fosgonimeton would be more readily absorbed and would convert to Dihexa in vivo (in living organisms), achieving therapeutic concentrations in the central nervous system [Athira Pharma, 2019].

Fosgonimeton entered clinical development as a potential treatment for Alzheimer's disease, mild cognitive impairment, and related neurodegenerative conditions. For approximately 5 years (2019-2024), it represented the most advanced clinical development of Dihexa-based therapeutics.

Understanding Prodrugs: Key Concept

A prodrug is chemically distinct from its active metabolite but produces therapeutic effects by being converted to the active drug in the body. Common pharmaceutical examples include codeine (a prodrug of morphine) and enalapril (a prodrug of enalaprilat, an ACE inhibitor).

Prodrugs are used when:

  • The active drug is poorly bioavailable when administered directly
  • The active drug is metabolised too quickly (short half-life)
  • The active drug is poorly soluble or difficult to formulate
  • Route-specific delivery is desired (e.g., converting a peptide into an orally available form)

In fosgonimeton's case, the prodrug strategy was intended to improve Dihexa's bioavailability when administered intravenously. However, bioavailability improvement is only valuable if the resulting systemic exposure translates to therapeutic benefit—a premise that fosgonimeton ultimately failed to validate in clinical trials.

Athira Pharma: Company History

Origins: M3 Biotechnology

Athira Pharma was founded in 2004 as M3 Biotechnology. The company was established by Leen Kawas, a neuroscientist at the University of Washington, and colleagues to develop novel therapeutics for neurodegeneration. The foundational research behind Dihexa emerged from Kawas's academic laboratory at the University of Washington during the early 2000s.

Kawas's laboratory published research demonstrating that HGF (hepatocyte growth factor) and related growth factors could reverse neurodegeneration in animal models of Alzheimer's disease. Based on this research, Kawas and his team identified Dihexa as a compound capable of activating HGF signalling and promoting neuroplasticity [Kawas, 2007].

Corporate Development (2004-2019)

M3 Biotechnology operated as a private company for 15 years, building an intellectual property portfolio around Dihexa and related compounds. The company secured funding from venture capital investors and biotech-focused institutional investors, raising approximately $100+ million over its existence. For much of this period, M3 operated in relative obscurity, with research and development proceeding without major clinical trials.

Transition to Athira Pharma (2019)

In 2019, M3 Biotechnology was renamed Athira Pharma. This rebranding coincided with acceleration toward clinical development. Athira initiated fosgonimeton's clinical development program, with the goal of obtaining FDA approval for Alzheimer's disease treatment. The company pursued an accelerated development pathway, attempting to reach late-stage clinical trials within 3-4 years.

IPO and Public Markets (2020)

In June 2020, Athira Pharma went public on the NASDAQ under ticker symbol ATHA. The IPO raised approximately $86 million and valued the company at over $300 million. The company's pitch to public markets emphasised Dihexa's mechanism, the strength of preclinical data, and the potential for Alzheimer's disease treatment in an enormous, underserved patient population.

At the time of the IPO, Phase 1 safety data from fosgonimeton trials appeared positive, creating investor enthusiasm for the company's clinical pipeline.

The Research Integrity Scandal: Leen Kawas and Falsified Data

The credibility of Athira Pharma's entire Dihexa program was fundamentally undermined in 2021 by revelation of research misconduct in the company's foundational science.

Critical Research Scandal: In 2021, Leen Kawas, Athira Pharma's co-founder and Chief Scientific Officer, resigned following discovery that foundational research images had been falsified. Kawas had published papers claiming to show HGF-mediated reversal of neurodegeneration in Alzheimer's disease mouse models. Subsequent investigation revealed that images purporting to show neurological improvement had been doctored—the same image sections were reused across multiple papers, and image manipulation software had been applied to create the appearance of treatment effects that did not actually exist [Retraction Watch, 2021].

Timeline of the Scandal

In 2021, following an investigation by the University of Washington and subsequent media scrutiny, Leen Kawas resigned from Athira Pharma. Multiple papers authored by Kawas's laboratory were identified as containing falsified image data. The University of Washington opened formal misconduct investigations, and several papers were retracted from peer-reviewed journals.

The images in question were central to the basic science justification for Dihexa's therapeutic potential. If these images were falsified, the fundamental evidence that HGF/c-Met pathway activation reversed neurodegeneration in Alzheimer's disease models became questionable.

Implications for Dihexa's Scientific Foundation

The Kawas scandal created profound uncertainty about Dihexa's basic science. While Dihexa does activate HGF/c-Met signalling (this mechanism was not disputed), the claim that this activation produces meaningful reversal of Alzheimer's pathology rested substantially on Kawas's animal studies. If those studies contained fabricated data, the theoretical basis for fosgonimeton's clinical development was weakened considerably.

Athira Pharma issued statements acknowledging the investigation, accepting Kawas's resignation, and asserting that the company's clinical development was proceeding independently of the compromised basic research. However, the reputational damage was severe. Investors questioned whether the entire scientific foundation was sound.

Clinical Trial Timeline and Results Overview

Despite the research scandal, Athira Pharma continued clinical development of fosgonimeton. Between 2017 and 2024, the company conducted four separate clinical trial programs testing fosgonimeton in Alzheimer's disease and Parkinson's disease. All trials either failed or produced concerning safety signals.

Phase 1 Clinical Trials (2017-2018): Safety and Tolerability

Fosgonimeton's initial Phase 1 trials evaluated basic safety, tolerability, and pharmacokinetics in healthy volunteers and mild-to-moderate Alzheimer's disease patients.

Trial Design

Phase 1 trials are the earliest human studies, typically enrolling 20-100 participants, with primary focus on safety rather than efficacy. Athira's Phase 1 program evaluated single and multiple ascending doses of fosgonimeton administered intravenously in healthy volunteers and in patients with early Alzheimer's disease.

Results

The Phase 1 trials reported that fosgonimeton was generally safe and well-tolerated across the dose ranges tested. No serious adverse events were attributed to fosgonimeton. Common adverse events were mild and typical of intravenous administration (e.g., injection site reactions, headache, mild nausea). Pharmacokinetic data showed that fosgonimeton was rapidly converted to Dihexa in circulation, as intended [Athira Pharma, 2018].

Significance

The positive Phase 1 results provided the rationale for advancing to Phase 2 efficacy trials. They did not demonstrate that fosgonimeton was effective for any disease—only that it did not cause significant acute toxicity. Phase 1 success is a relatively low bar; the critical test comes in Phase 2, where efficacy is assessed.

Phase 2 ACT-AD Trial (2022): First Efficacy Failure

The ACT-AD trial (Athira Clinical Trial—Alzheimer's Disease) was designed to evaluate fosgonimeton's efficacy in patients with mild-to-moderate Alzheimer's disease. This was Athira's first opportunity to demonstrate cognitive benefit from fosgonimeton treatment.

Trial Design

ACT-AD was a randomised, double-blind, placebo-controlled Phase 2 trial enrolling approximately 170 patients with mild-to-moderate Alzheimer's disease. Patients received either fosgonimeton (at a specific dose) or placebo via intravenous infusion on a weekly schedule for 12 weeks, followed by 12 weeks of observation. The primary endpoint was change in ADAS-cog (Alzheimer's Disease Assessment Scale—cognitive subscale), a standard measure of cognitive function in Alzheimer's trials.

Results and Failure

In 2022, Athira announced that ACT-AD had failed its primary endpoint. Fosgonimeton did not produce significantly greater cognitive improvement than placebo. The difference between fosgonimeton and placebo groups was not statistically significant [Athira Pharma, 2022].

This was a critical setback. The trial had been powered to detect a clinically meaningful difference. The failure to achieve this suggested that fosgonimeton simply did not improve cognition in Alzheimer's disease patients, at least not through the mechanism and at the doses tested.

Post-Hoc Analysis and Reframing

Following the primary endpoint failure, Athira conducted post-hoc subgroup analyses, examining whether fosgonimeton might benefit specific patient subgroups (e.g., patients with specific biomarker profiles, earlier disease stages, or specific APOE genotypes). Some subgroups showed numerical trends favouring fosgonimeton, though these analyses were conducted after the trial ended and lack the statistical power of the pre-specified primary analysis. Post-hoc subgroup analyses are generally considered exploratory and have low evidential value—they are useful for hypothesis generation but not confirmation.

Athira used the post-hoc analysis to justify proceeding to a larger Phase 2/3 trial (LIFT-AD) with modified inclusion criteria, attempting to identify a population where fosgonimeton might work.

Phase 2/3 LIFT-AD Trial (September 2024): Complete Failure

The LIFT-AD trial (Launching Initiatives to Focus on Tau-driven disease—Alzheimer's Disease) was Athira's most ambitious trial, designed as a large Phase 2/3 study intended to provide pivotal efficacy data for potential FDA approval. It incorporated modifications based on ACT-AD's post-hoc subgroup findings.

Trial Design Modifications

LIFT-AD enrolled a modified patient population based on post-hoc findings from ACT-AD. The trial enrolled approximately 500 patients with mild cognitive impairment or mild dementia due to Alzheimer's disease. Critically, LIFT-AD enrolled patients enriched for amyloid and tau biomarkers—the pathological hallmarks of Alzheimer's disease. This biomarker enrichment was intended to identify patients most likely to respond to fosgonimeton.

Patients received fosgonimeton or placebo via intravenous infusion on a 2-week schedule for 52 weeks (approximately one year of treatment). The trial had multiple primary and secondary endpoints assessing cognitive function, functional ability, and biomarker changes.

September 2024: Complete Failure

In September 2024, Athira announced that LIFT-AD had failed both its primary endpoints and all key secondary endpoints. Fosgonimeton did not produce significantly greater cognitive improvement than placebo, nor did it produce significantly greater functional improvement than placebo. Biomarker endpoints also failed to show significant benefit [Athira Pharma, 2024].

This was a catastrophic failure. LIFT-AD was the company's definitive pivotal trial, designed to generate evidence suitable for FDA submission. The complete failure of all primary and key secondary endpoints meant that there was no reasonable pathway to FDA approval for fosgonimeton in Alzheimer's disease.

What LIFT-AD Failure Means

The LIFT-AD failure is the most powerful evidence that fosgonimeton does not provide cognitive or functional benefit in Alzheimer's disease, at least at the doses and treatment durations tested. The trial was large (500 patients), well-designed, and specifically enriched for patients with biomarkers most likely to respond. The failure of all endpoints was not marginal—it was complete.

This failure raises fundamental questions about whether HGF/c-Met pathway activation, despite its theoretical appeal and animal model support, actually translates to clinical benefit in human Alzheimer's disease. The clinical translation gap between animal models and human disease remains poorly understood.

Fosgonimeton in Parkinson's Disease: Safety Concerns

While fosgonimeton failed in Alzheimer's disease, Athira also conducted a Phase 2 trial in Parkinson's disease patients, hypothesising that HGF/c-Met pathway activation might benefit a different neurodegenerative condition.

Trial Details

Athira conducted a Phase 2 trial evaluating fosgonimeton in early-stage Parkinson's disease patients. The trial tested two dose levels of fosgonimeton versus placebo. The primary endpoint was change in motor symptom severity (measured by the Unified Parkinson's Disease Rating Scale—UPDRS).

Results: Dose-Dependent Adverse Events

The Parkinson's trial reported concerning safety findings. In the high-dose fosgonimeton group, 4 out of 10 patients discontinued treatment due to adverse events. The adverse events included psychiatric symptoms, motor deterioration, and other neurological effects. The low-dose group tolerated treatment better, but efficacy signals were absent.

These findings raised the possibility that fosgonimeton might actually accelerate neurological decline in Parkinson's disease patients—the opposite of the intended therapeutic effect. The mechanism for this potential paradoxical effect is unknown but suggests that HGF/c-Met pathway activation might have disease-specific or dose-specific negative effects in some patient populations.

ATH-1105: ALS Pipeline and Ongoing Development

Following fosgonimeton's failure in Alzheimer's disease, Athira attempted to redirect its HGF/c-Met pathway platform toward other neurodegenerative diseases. The company developed ATH-1105, a purportedly improved version of the HGF/c-Met pathway activator, for testing in Amyotrophic Lateral Sclerosis (ALS).

Current Status (2025)

As of April 2026, ATH-1105 remains in preclinical or early clinical development for ALS. No Phase 2 or Phase 3 data has been published. The compound has not yet demonstrated clinical efficacy in human subjects. Development appears to be proceeding at a slower pace than fosgonimeton's development did, possibly due to the company's financial constraints following Alzheimer's trial failures and the broader loss of investor confidence.

Investor Confidence

Athira's stock price collapsed following the LIFT-AD failure announcement. The company's market capitalisation, which had exceeded $300 million at IPO, declined to less than $100 million following the trial failure. This loss of financial resources constrains the company's ability to pursue expensive late-stage clinical development.

January 2025: False Claims Act Settlement

In January 2025, the U.S. Department of Justice announced that Athira Pharma had agreed to settle a False Claims Act lawsuit for $4 million. The settlement related to allegations that the company had made false claims to the National Institutes of Health (NIH) regarding its scientific research.

Nature of the Settlement

The settlement specified that Athira had submitted NIH grant applications and reports that included claims based on the research data later identified as falsified or manipulated—the same research integrity issues involving Leen Kawas's laboratory data. The company allegedly did not adequately disclose the research misconduct investigations to NIH when applying for and reporting on federally funded grants.

The settlement did not constitute an admission of wrongdoing but did require payment of $4 million and implementation of enhanced scientific oversight and data integrity procedures.

Significance

The 2025 settlement reinforced public knowledge that Athira's foundational research had been compromised. It demonstrated that the company had potentially misrepresented the integrity of its basic science data to federal funding agencies. This further damaged the company's credibility and the plausibility of its core scientific claims.

Critical Distinction: Fosgonimeton ≠ Dihexa

Fosgonimeton and Dihexa are not identical compounds: Fosgonimeton is a phosphate ester prodrug of Dihexa designed for intravenous administration in clinical trials. Raw Dihexa is a peptide sold as a research chemical, typically administered intranasally. They differ in chemical structure (phosphate vs non-phosphate), route of administration (intravenous vs intranasal), metabolic fate, bioavailability, and clinical context (pharmaceutical development vs research chemical). Clinical trial failures of fosgonimeton do not necessarily predict outcomes of raw Dihexa use, but they do raise important mechanistic questions about whether HGF/c-Met pathway activation translates to clinical benefit in human neurodegenerative disease.

Chemical Differences

Fosgonimeton is Dihexa with a phosphate group attached. This modification alters its pharmacokinetics, bioavailability, and metabolism. When administered intravenously, fosgonimeton is rapidly dephosphorylated to produce Dihexa. However, the prodrug form itself may have distinct biological activity from raw Dihexa. The phosphate group affects protein binding, cellular uptake, and tissue distribution.

Route of Administration Differences

Fosgonimeton was administered intravenously in clinical trials, bypassing the blood-brain barrier via systemic circulation and achieving high systemic concentrations. Raw Dihexa sold as a research chemical is typically self-administered intranasally, attempting to achieve direct brain penetration via olfactory nerve access.

These routes produce entirely different pharmacokinetic profiles. Intravenous administration creates high, transient blood levels; intranasal administration may bypass systemic circulation entirely, targeting the central nervous system directly.

Patient Population Differences

Fosgonimeton clinical trials enrolled patients with diagnosed Alzheimer's disease or mild cognitive impairment—individuals with established neurological pathology. Raw Dihexa use by biohackers and researchers involves healthy individuals or individuals with normal age-related cognitive aging, not diagnosed neurodegenerative disease.

A compound might fail to improve cognitive function in Alzheimer's disease patients (where neurons are dying and pathology is advanced) but still potentially slow cognitive aging in healthy individuals or those with mild age-related changes. The patient populations are fundamentally different.

Dose and Duration Differences

Fosgonimeton clinical trials used standardised doses administered by healthcare professionals on regular schedules (weekly or bi-weekly for 12-52 weeks). Self-administered raw Dihexa dosing is variable, uncontrolled, and sometimes much lower than clinical trial doses. Chronic effects might emerge with different dosing patterns than those tested clinically.

What Fosgonimeton's Clinical Failures Mean for Dihexa Users

The complete failure of fosgonimeton in Alzheimer's disease clinical trials raises important questions about raw Dihexa use, but it does not provide a direct answer about whether Dihexa is effective or safe.

Interpretation 1: The Pessimistic View

The fosgonimeton failures suggest that HGF/c-Met pathway activation, despite its theoretical appeal and animal model support, does not translate to meaningful clinical benefit in human neurodegenerative disease. If activating HGF/c-Met were as powerful as animal studies suggested, fosgonimeton should have demonstrated benefit in Alzheimer's disease patients. The fact that it did not raises the possibility that:

  • The animal models were misleading or not predictive of human pathology
  • The dose or duration of treatment was insufficient
  • The mechanism does not actually engage as predicted in human brains
  • Therapeutic benefit, if it exists, is much smaller than preclinical data suggested

Under this interpretation, raw Dihexa might similarly fail to produce meaningful cognitive benefit in humans, despite theoretical mechanism.

Interpretation 2: The Cautious but Less Pessimistic View

Fosgonimeton's failure in Alzheimer's disease does not necessarily predict outcomes in healthy individuals or those with normal aging. Several factors complicate direct translation:

  • Alzheimer's disease involves extensive neuronal death, amyloid pathology, and tau tangles. At this stage, promoting new synapse formation might be insufficient to overcome massive neuronal loss.
  • Intranasal Dihexa might achieve different brain concentrations than intravenous fosgonimeton.
  • Healthy aging brains might respond differently to neuroplasticity promotion than disease brains.
  • Long-term low-dose effects might differ from pharmaceutical-trial-dose effects.

Under this interpretation, raw Dihexa might still produce cognitive benefits in healthy individuals for prevention, even if fosgonimeton fails as an Alzheimer's disease treatment.

Interpretation 3: The Honest Uncertainty

The truthful answer is that fosgonimeton's clinical failures are concerning and raise legitimate questions about HGF/c-Met pathway activation, but they do not definitively answer whether raw Dihexa use produces cognitive benefit. The clinical failures create uncertainty—uncertainty that should inform caution about Dihexa use. Any individual considering Dihexa should understand that:

  • The theoretical mechanism, while compelling, has not been validated in human clinical trials.
  • Animal models proved to be unreliable guides to human efficacy.
  • The foundational research has significant integrity concerns.
  • No evidence of cognitive benefit in humans currently exists.
  • Safety in long-term human use is essentially unknown.

The Research Integrity Problem

Perhaps most importantly, the Leen Kawas data falsification scandal means that the basic scientific justification for HGF/c-Met pathway activation rests on compromised data. While subsequent research has confirmed that HGF/c-Met activation occurs in animal neurons, the critical claim that this activation reverses neurodegeneration rested substantially on Kawas's falsified studies. This foundational uncertainty adds another layer of caution.

Conclusion: What We Know and Don't Know

What We Know

  • Fosgonimeton (Dihexa's prodrug) is safe in Phase 1 trials and does not produce acute toxicity at tested doses.
  • Fosgonimeton failed to improve cognition or function in Alzheimer's disease patients in two Phase 2/3 trials (ACT-AD and LIFT-AD).
  • Fosgonimeton produced concerning dose-dependent adverse effects (psychiatric symptoms, motor deterioration) in Parkinson's disease patients.
  • Athira Pharma's foundational research involves falsified data and research misconduct by Leen Kawas.
  • The company settled a False Claims Act lawsuit in 2025 related to misrepresented research integrity.
  • Raw Dihexa is chemically, pharmacologically, and clinically distinct from fosgonimeton in multiple ways.

What We Don't Know

  • Whether intranasal raw Dihexa produces cognitive benefits in healthy individuals.
  • Whether long-term Dihexa use has safety risks that did not emerge in short-term clinical trials.
  • Whether Dihexa's theoretical neuroplasticity-enhancing mechanism actually engages in human brains at any dose or duration.
  • Whether raw Dihexa differs in biological activity from fosgonimeton in ways that might produce different clinical outcomes.
  • What optimal dosing, frequency, and duration would be for any potential cognitive enhancement.
  • Whether any observed cognitive effects in self-reporting Dihexa users result from the compound or from placebo effect, selection bias, or other confounders.

References & Further Reading